+ Watch MR
on My Watchlist
The Company is a developer, manufacturer and marketer of medical devices in China.
Downtrended stock I would pay no more than $14 for barring earnings surprises.
From the value investor's perspective, Mindray stands out as a reliably impressive performer considering its ROE, ROA, 5 year trailing earnings growth, and quick ratio. MR touts its improved cash conversion cycle as a strength; indeed, my observations of its ROE, 5 year trailing earnings growth > 23%, and quick ratio also reveal strong internal management.
This business group is too valuable specially in the field of medicines not to able to outperform the S&P 500 in a whole year period. On time past, it outperform the index between February and August many times. It will do the same over future periods since Chinese Medicinal technology is already proven high integrity.
Great growth prospects. I don't see why this one isn't getting bought out.
Mindray will outperform the market because it developed a "marubozu" candle, on massive volume, this month and it's going higher (https://sites.google.com/site/higheralphaideas/home/combiningfundamentalsandtechnicalstoproducesuperiorresults). A bullish marubozu candle shows buying interest the entire trading day. There are either no tails (shadows) or very small tails on the candle. It opens with a gap up and the buying interest never slows, trending higher all session long and finishing at or very near its high of the day.
chinese stock rated #13 top rated world stocks.
This company is in the right place at the right time
(JJ) Good earnings growth, well positioned to continue growing in an emerging market. Credible accounting.
With PricewaterhouseCoopers as its audit firm, there's much less of a concern about the integrity of the financial reports as is the case with other China based companies. I see this stock doing well when China stocks swing in favor. And I am putting my money where my mouth is...I invested today...this takes the China spot in my portfolio.
I'm in China often. The level of medical care needs strong infrastructure improvement, including equipment. I'm surprised the China government hasn't put this as one of their very high priorities. MR will be poised to take advantage when this focus happens.
After adjusting the share price downward to reflect the company's net cash position of $3.70 per share, I calculate that Mindray Medical is selling for about 14 times its forward eps. Considering this company's impressive operations history and outstanding growth prospects as a Chinese maker of medical devices, this seems like a deal. The auditor is Price Waterhouse Coopers - so not much chance of fraud.
Paying off debt, rising sales, constant profit growth.
Stock screen results. Using ROE, PE, LT debt/Equity, Current Ratio.
you know why.....
another good chinese story in healthcare
Chinese medical equipment supplier. I am going to hold my breath and not buy into the stereotype that everything made in China is bad. As the median age continues to increase, Chinese are going to have to spend their savings on something, and it is as likely to be medical care as education.
Looking for "THE" China Play
p/e kinda high. picked anyway
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions